



**Grant Thornton**

An instinct for growth™

# **Glenmark Holding SA La Chaux-de-Fonds**

Financial Statements  
for the Year ended March 31, 2020  
and Report of the Statutory Auditor





# Grant Thornton

An instinct for growth™

---

**Grant Thornton AG**

Rue du 31-Décembre 47

P.O. Box 6388

CH-1211 Genève 6

T +41 22 718 41 41

F +41 22 718 41 40

[www.grantthornton.ch](http://www.grantthornton.ch)

## Report of the Statutory Auditor

To the General Meeting of the Shareholders of  
**Glenmark Holding SA, La Chaux-de-Fonds**

### Report of the Statutory Auditor on the Financial Statements

As statutory auditor, we have audited the accompanying financial statements of Glenmark Holding SA, which comprise the balance sheet, income statement, and notes for the year ended March 31, 2020.

### Board of Directors' Responsibility

The Board of Directors is responsible for the preparation of the financial statements in accordance with the requirements of Swiss law and the Company's articles of incorporation. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Board of Directors is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

### Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control system relevant to the entity's preparation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control system. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



# Grant Thornton

An instinct for growth™

## **Opinion**

In our opinion, the financial statements for the year ended March 31, 2020 comply with Swiss law and the Company's articles of incorporation.

## **Report on Other Legal Requirements**

We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence (article 728 CO) and that there are no circumstances incompatible with our independence.

In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of financial statements according to the instructions of the Board of Directors.

We recommend that the financial statements submitted to you be approved.

We draw attention to the fact that half of the share capital and legal reserves are no longer covered (article 725 para. 1 CO).

Geneva, September 28, 2020

**Grant Thornton AG**

Erich Bucher  
Audit Expert  
Auditor in charge

Moritz Herbst

## Enclosure:

- Financial statements (balance sheet, income statement, and notes)



**Glenmark HOLDING SA**  
La Chaux-de-Fonds, Switzerland

<b>Balance sheet as at</b>	<u>31.03.2020</u>	<u>31.03.2019</u>
<b>Assets</b>		
	<i>(in Swiss francs)</i>	
<b>Current assets</b>		
Cash and cash equivalents	<b>796'280</b>	<b>805'573</b>
Accounts receivables -	<b>8'840'110</b>	<b>2'507'585</b>
due from group companies	<i>8'840'110</i>	<i>2'507'585</i>
Other current receivables	<b>55'340</b>	<b>42'444</b>
due from third parties	<i>55'340</i>	<i>42'444</i>
<b>Total current assets</b>	<b>9'691'729</b>	<b>3'355'602</b>
<b>Non-current assets</b>		
Financial assets -	<b>108'424'088</b>	<b>125'150'605</b>
Long-term receivables from group companies	<i>108'424'088</i>	<i>125'150'605</i>
Investments in group companies	<b>1'206'791'668</b>	<b>1'079'987'235</b>
<b>Total non-current assets</b>	<b>1'315'215'756</b>	<b>1'205'137'841</b>
<b>Total assets</b>	<b>1'324'907'486</b>	<b>1'208'493'443</b>



**Glenmark HOLDING SA**  
La Chaux-de-Fonds, Switzerland

<b>Balance sheet as at</b>	<u>31.03.2020</u>	<u>31.03.2019</u>
<b>Liabilities</b>		
	<i>(in Swiss francs)</i>	
<b>Short-term liabilities</b>		
Accounts payables -	<b>30'288'829</b>	<b>50'661'346</b>
due to third parties	494'375	1'864'383
due to group companies	44'310	-
due to shareholders	29'750'144.33	48'796'963
Short-term interest-bearing liabilities -	<b>49'338'375</b>	<b>82'087'500</b>
due to third parties	49'338'375	82'087'500
Accrued expenses and deferred income	<b>71'353</b>	<b>3'414</b>
<b>Total short-term liabilities</b>	<b>79'698'557</b>	<b>132'752'259</b>
<b>Long-term liabilities</b>		
Long-term interest-bearing liabilities -	<b>999'523'275</b>	<b>952'448'565</b>
due to third parties	117'449'400	106'547'917
due to shareholders	882'073'875	845'900'648
Provision for unrealized translation gain	<b>22'364'305</b>	<b>970'939</b>
<b>Total long-term liabilities</b>	<b>1'021'887'580</b>	<b>953'419'504</b>
<b>Shareholders' equity</b>		
Share capital	<b>442'239'894</b>	<b>242'239'894</b>
Legal retained earnings	<b>11'377'084</b>	<b>11'377'084</b>
General legal retained earnings	11'377'084	11'377'084
Legal capital reserves	<b>149'691'302</b>	<b>149'691'302</b>
Reserves from capital contribution	149'691'302	149'691'302
Accumulated deficit	<b>(379'986'932 )</b>	<b>(280'986'600 )</b>
Accumulated losses brought forward	(280'986'600 )	(61'954'147 )
Loss for the year	(99'000'332 )	(219'032'453 )
<b>Total shareholders' equity</b>	<b>223'321'348</b>	<b>122'321'680</b>
<b>Total liabilities and shareholders' equity</b>	<b>1'324'907'486</b>	<b>1'208'493'443</b>



**Glenmark HOLDING SA**  
La Chaux-de-Fonds, Switzerland

**Profit and loss statement for the financial year/period ended**

31.03.2020

31.03.2019

*(in Swiss francs)*

Professional service cost	(2'613'547 )	(287'410 )
Administrative expenses	(20'774 )	(10'762 )
Depreciation and valuation adjustments to fixed assets		
Other operating expenses	(185'665 )	(393'322 )
<b>Loss for the year before interest and taxes</b>	<b>(2'819'986 )</b>	<b>(691'495 )</b>
Financial income	34'781'717	23'611'155
Financial expenses	(70'210'070 )	(82'293'676 )
<b>Loss for the year before taxes</b>	<b>(38'248'339 )</b>	<b>(59'374'015 )</b>
Non-operating expenses	-	-
Extraordinary, non-recurring or prior-period expenses	(60'750'171 )	(159'657'434 )
<b>Loss for the year before taxes</b>	<b>(98'998'510 )</b>	<b>(219'031'449 )</b>
Taxes	(1'822 )	(1'004 )
<b>Loss for the year</b>	<b>(99'000'332 )</b>	<b>(219'032'453 )</b>



## **Notes to the financial statements**

### **GLENMARK SIGNIFICANT ACCOUNTING POLICIES**

- **Basis of preparation**

These financial statements have been prepared in accordance with the provisions of commercial accounting as set out in the Swiss Code of Obligations (Art. 957 to 963b CO, effective since 1 January 2013). The consolidation is performed at Group level.

- **Foreign currency transactions**

Transactions in foreign currencies are converted into CHF at the prevailing exchange rate on the transaction date. Balance sheet items in foreign currency are converted using the year-end exchange rate. Exchange differences, except for unrealized gains which are deferred, are included in the determination of net income

- **Impairment of assets**

The Company assesses at each Balance Sheet date whether there is any indication that assets may be impaired. If any such indication exists, the Company estimates the recoverable amount of the cash generating unit to which the assets belong. If the recoverable amount of the cash generating unit to which the assets belong is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The recoverable amount is higher of the value in use and realizable value.

The reduction is treated as an impairment loss and is recognized in the Statement of Profit and Loss.

If, at the Balance Sheet date, there is an indication that a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount.

\*\*\*



## Glenmark HOLDING SA

La Chaux-de-Fonds, Switzerland

### Notes to the financial statements

(in Swiss francs)

#### Details, analyses and explanations to the financial statements

The number of full-time equivalents did not exceed 10 on an annual average basis.

#### Investments in group companies

	2020		2019
	Capital	Votes	Votes
▫ Ichnos Sciences SA (Former Glenmark Pharmaceuticals SA) , La Chaux-de-	CHF 156'514'325	100%	100%
▫ Glenmark Specialty SA, La Chaux-de-Fonds Switzerland	CHF 30'000'000	100%	100%
▫ Glenmark Farmacêutica Ltda, São Paulo, Brazil	BRL 479'523'760	100%	100%
▫ Glenmark Pharmaceuticals s.r.o., Prague, Czech Republic	CZK 60'000'000	100%	100%
▫ Glenmark Distributors s.r.o., Prague, Czech Republic	CZK 10'000'000	100%	100%
▫ Glenmark Pharmaceuticals S.R.L., Bucharest, Romania	RON 1'702'500	100%	100%
▫ Glenmark Pharmaceuticals Sp.z.o.o, Warsaw, Poland	PLN 5'000'000	100%	100%
▫ Glenmark Distributors Sp.z.o.o, Warsaw, Poland	PLN 1'850'000	100%	100%
▫ Glenmark Pharmaceuticals Europe R&D Ltd, Kenton, Middlesex, U.K.	GBP 800'708	100%	100%
▫ Glenmark Therapeutics Inc., NJ Mahwah USA	USD 1.36	100%	100%
▫ Viso Farmaceutica SL, Madrid Spain	EUR 3'000	100%	100%
▫ Glenmark Pharmaceuticals Inc., NJ Mahwah USA	USD 6.67	100%	100%
▫ Glenmark Generics SA, Buenos Aires, Argentina	ARS 1'630'612'430	100%	100%
▫ Glenmark Arzneimittel GmbH, Gröbenzell, Germany	EUR 50'000	100%	100%
▫ Glenmark Pharmaceuticals B.V. Amsterdam Holland	EUR 18'000	100%	100%
▫ Glenmark Pharmaceuticals Nordic AB, Goeteborg, Sweden	SEK 50'000	100%	100%
▫ Glenmark Pharmaceuticals Inc Canada, Fredericton NB, Ontario	CAD 2'110'600	100%	100%
▫ Glenmark Ukraine LLC, Kiev, Ukraine	UAH 18'538'305	100%	100%
▫ Ichnos Sciences Inc., Delaware, USA	USD 1	100%	-

#### Group VAT

Ichnos Sciences SA, Glenmark Holding SA, Glenmark Specialty SA and Ichnos Sciences Biotherapeutics SA are in the same VAT group and jointly responsible.

#### Explanations of extraordinary, non-recurring or prior-period items in the profit and loss statement

As a result of a strategic objective undertaken by management, a decision was taken by the shareholding company, Glenmark Holding SA, to waive an amount of CHF 4'015'639 of the loans granted to the Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), and to convert an amount of CHF 153'380'628 into share capital and capital contribution of which CHF 46'822'303 has been considered as impairment of the investment held in Ichnos Sciences SA.

As Glenmark Pharmaceuticals S.R.L., Bucharest, went through liquidation process, an impairment of CHF 9'868'229 was recorded.

#### Significant events after the balance sheet date:

As far as currently known, the first cases of coronavirus in humans became known at the end of 2019, when the spread was locally limited. Only the significant expansion of the coronavirus since January 2020 has led to the current economic effects. In our opinion, the occurrence of the coronavirus is a global threat. With regard to the annual financial statements as of 31 March 2020, it is not considered an event subsequent to the balance sheet date with a material effect on such financial statements.

While the spread of the coronavirus has a negative impact on business activities, it is currently not possible to make a reliable estimate on the depth of the impact on business activities. We assume that this does not represent a threat to the company's ability to continue as a going concern.

There are no other events after the balance sheet date that require disclosure.